PLASMA CELL LEUKEMIA
Clinical trials for PLASMA CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for PLASMA CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancer: QUANTUM trial tests targeted therapy after transplant
Disease control Not yet recruitingThis study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail aims to beat myeloma
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental CAR-T therapy targets tough blood cancers in early trial
Disease control Not yet recruitingThis early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC